Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis
- Author:
Sang Hoon LEE
1
;
Yoomi YEO
;
Tae Hyung KIM
;
Hong Lyeol LEE
;
Jin Hwa LEE
;
Yong Bum PARK
;
Jong Sun PARK
;
Yee Hyung KIM
;
Jin Woo SONG
;
Byung Woo JHUN
;
Hyun Jung KIM
;
Jinkyeong PARK
;
Soo Taek UH
;
Young Whan KIM
;
Dong Soon KIM
;
Moo Suk PARK
;
Author Information
- Publication Type:Meta-Analysis
- Keywords: Idiopathic Pulmonary Fibrosis; Diagnosis; Disease Management; Korea
- MeSH: Delivery of Health Care; Diagnosis; Disease Management; Dyspnea; Epidemiology; Humans; Idiopathic Pulmonary Fibrosis; Korea; Lung Diseases, Interstitial; Lung Transplantation; Prognosis; Risk Factors; Tuberculosis
- From:Tuberculosis and Respiratory Diseases 2019;82(2):102-117
- CountryRepublic of Korea
- Language:English
- Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia, which presents with a progressive worsening dyspnea, and thus a poor outcome. The members of the Korean Academy of Tuberculosis and Respiratory Diseases as well as the participating members of the Korea Interstitial Lung Disease Study Group drafted this clinical practice guideline for IPF management. This guideline includes a wide range of topics, including the epidemiology, pathogenesis, risk factors, clinical features, diagnosis, treatment, prognosis, and acute exacerbation of IPF in Korea. Additionally, we suggested the PICO for the use of pirfenidone and nintendanib and for lung transplantation for the treatment of patients with IPF through a systemic literature review using experts' help in conducting a meta-analysis. We recommend this guideline to physicians, other health care professionals, and government personnel in Korea, to facilitate the treatment of patients with IPF.
